check_circleStudy Completed

Primary PAH (Pulmonary Arterial Hypertension)

Crossover St.: Iloprost Nebulizer vs. Prodose Neb.

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 - 45 Years
  • -

  • -

Trial summary

Enrollment Goal
20
Trial Dates
April 2007 - May 2007
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Ventavis (Iloprost, BAYQ6256)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

A randomized, open-label, single center, crossover study to compare pharmacokinetics in healthy male volunteers following inhalation of 5 mcg iloprost as aerosol generated from Ventavis by two distinct nebulizing devices
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A